REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial

RegenXBio shared positive updates from their Phase 1/2 AAV micro-dystrophin gene therapy clinical trial for individuals with Duchenne aged 4-11 years old. 

The 3 individuals in the lowest dose cohort all demonstrated reductions in CK levels, and expression of micro-dystrophin averaging 44% at 3 months. 

Enrollment is also complete for a second cohort, which will receive a higher dose of the experimental therapy.  RegenXBio plans to share initial strength and functional data for both dose levels and initiate a pivotal trial in the second half of this year. 

READ THE FULL PRESS RELEASE HERE